The number of people with susceptibility test result for rifampicin in Czechia
Czechia: The number of people with susceptibility test result for rifampicin was 89.51 in 2021. ▬ Flat
Latest (2021)
89.51
Change on year
up 5.6%
World rank
68th
of 146 countries
All-time high
89.51
in 2021
All-time low
84.79
in 2020
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Czechia, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Czechia recorded 89.51 for the number of people with susceptibility test result for rifampicin in 2021. That is the highest value across all 5 years on record.
That represents a change of up 5.6% on the previous year and up 4.3% over five years.
Czechia ranks 68th of 146 countries on this measure, in the middle of the range.
The number of people with susceptibility test result for rifampicin in Czechia, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 85.8 | — |
| 2018 | 86.34 | +0.6% |
| 2019 | 87.25 | +1.1% |
| 2020 | 84.79 | -2.8% |
| 2021 | 89.51 | +5.6% |
Czechia compared with similar countries
- Czechia's 89.51 is below the median for high income countries, which is 92.6, 97% of the median. (56 countries reporting)
- Czechia's 89.51 is below the median for Europe & Central Asia, which is 93.52, 96% of the median. (43 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 86.46 | 85.8 | 87.25 | 3 |
| 2020s | 87.15 | 84.79 | 89.51 | 2 |
Countries ranked near Czechia
More health data for Czechia
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.7726 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,169 deaths per 1,000 people (2090)
- Number of infants who die before age 1 34 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -5.76 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0222 units per person (2025)
- Population ages 00-04, male, annual growth rate -5.46 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Czechia?
- The number of people with susceptibility test result for rifampicin in Czechia was 89.51 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Czechia?
- The highest recorded value was 89.51 in 2021.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Czechia?
- The lowest recorded value was 84.79 in 2020.
- How does Czechia rank for the number of people with susceptibility test result for rifampicin?
- Czechia ranks 68th out of 146 countries with data for 2021.
- Where does this Czechia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).